Home / Going-concern warnings / AEON Biopharma, Inc.
Filed 2025-05-14 路 Form 10-Q 路 Accession 0001837607-25-000050 nano
Price before filing: $0.502 (2025-05-13 close, split/dividend-adjusted)
Market cap at flag: $5.5M (2025-05-14) 路 Latest: $11.7M (2026-10-16)
| Window | AEON | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +81.5% | +1.7% | +79.7% | 2025-06-13 |
| 90 days | +37.3% | +9.8% | +27.4% | 2025-08-12 |
| 180 days | +86.3% | +16.8% | +69.5% | 2025-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: no open-market insider sales or purchases reported.
30 days after: 1 insider bought $85K (3 purchases)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-05-14: red flag filed | |||||||
| 2025-05-19 | FISCHER JOST Director | Purchase | 50,000 | $0.50 | $25K | no | Form 4 |
| 2025-05-20 | FISCHER JOST Director | Purchase | 60,000 | $0.51 | $30K | no | Form 4 |
| 2025-05-21 | FISCHER JOST Director | Purchase | 60,000 | $0.49 | $29K | no | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-02-13 to 2025-06-13. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As a result of these conditions, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.